Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients

UnknownOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Idarubicin

8 mg/m2, iv drip on days 1-3

Trial Locations (1)

RECRUITING

Bing Xu, Guangzhou